Business
Kali-Extracts, Inc. Releases Preclinical Research Study Results on Therapy for Respiratory Disease Driving $11 Billion Treatment Market
Kali-Extracts, Inc. Releases Preclinical Research Study Results on Therapy for Respiratory Disease Driving $11 Billion Treatment Market.
About this update from Kali Inc
[{"type":"text","content":"\n\n\n\nKali-Extracts, Inc. Releases Preclinical Research Study Results on Therapy for Respiratory Disease Driving $11 Billion Treatment Market\n\n\n\n\n\nKali-Extracts, Inc. Releases Preclinical Research Study Results on Therapy for Respiratory Disease Driving $11 Billion Treatment Market\nPR Newswire\nDALLAS, December 19, 2018\n\n\n\nDALLAS, December 19, 2018 /PRNewswire/ --\n\nKali, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (\"KALY\") today announced the new Kali Cannabis Therapies subsidiary to develop cannabis biotechnology treatment alternatives to chemical pharmaceuticals.  On November 15th, 2018, KALY acquired NCM Biotech to include a patented cannabis extraction process and associated intellectual properties consisting of years of preclinical research studies surrounding a multitude of applications of cannabis extracts derived from the patented cannabis extraction process. The acquired cannabis biotechnology intellectual properties will be contained within the new Kali Cannabis Therapies subsidiary were ongoing research and development will be conducted for the purposes of producing cannabis treatments for specific conditions.\n\nKali-Extracts is today releasing summary results of one of many preclinical research studies in order to present an example of the underlying value of Kali-Extracts overall cannabis biotechnology intellectual properties.  An upcoming independent analyst research report on Kali-Extracts from Goldman Small Cap Research is expected to include a more comprehensive analysis of Kali-Extracts overall body of cannabis biotechnologies.\n\nNCM Biotech (acquired by Kali-Extracts) in collaboration with Beech Tree Labs, Inc. (BTL) of Providence, Rhode Island, conducted a series of in vitro genomic experiments to evaluate the potential of cannabis extracts derived from KALY's patented extraction process in the treatment of respiratory diseases.  The experiments were designed to evaluate pure cannabis extracts and cannabis extracts in combination with other therapies in the treatment of chronic obstructive pulmonary disease (COPD) and Asthma.  There are a significant number of genes associated with COPD and Asthma.  The experiments evaluated the ability of various formulations to change Asthma or COPD associated gene expressions in human small airway epithelial cells. &#...